Leo Pharma drags atopic eczema tablet through another phase I study

Although the dermatology firm’s candidate for atopic eczema has already made it through initial testing, and is also expecting data from now ongoing phase II studies this year, another phase I is needed to see its effects on the heart.

As a part of standard testing, Leo Pharma has to conduct an additional phase I trial of its potential atopic eczema tablet | Photo: Leo Pharma/PR

How a person’s heart rhythm could be affected by Leo Pharma’s candidate, LEO 152020, will be tested in a safety study including 28 healthy participants, according to database Clinical Trials.

LEO 152020 is a tablet currently undergoing both a phase II trial where it is being tried as a potential treatment for atopic eczema, and another phase II with cholinergic urticaria, also known as nettle rash, a condition which develops hives and itchy skin. The candidate has already gone through phase I testing.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs